Detalles de la búsqueda
1.
Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection.
J Viral Hepat
; 30(1): 64-72, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36302162
2.
Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs.
Value Health
; 26(6): 883-892, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36646278
3.
Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort.
J Viral Hepat
; 2022 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35583922
4.
Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
Clin Infect Dis
; 73(1): e69-e78, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32421194
5.
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs.
Clin Infect Dis
; 72(8): 1392-1400, 2021 04 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32166305
6.
Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection.
Hepatology
; 72(1): 7-18, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31652357
7.
Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study.
Clin Infect Dis
; 71(6): 1502-1510, 2020 09 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31585005
8.
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.
Clin Infect Dis
; 71(7): e115-e124, 2020 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31677262
9.
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
J Hepatol
; 72(3): 431-440, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31655134
10.
Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study.
J Viral Hepat
; 26(12): 1423-1430, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31448470
11.
Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay.
J Infect Dis
; 217(12): 1889-1896, 2018 05 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-29534185
12.
Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study.
Hepatology
; 64(6): 1911-1921, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27639183
13.
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
BMC Infect Dis
; 17(1): 420, 2017 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-28610605
14.
Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugs.
Int J Drug Policy
; 128: 104468, 2024 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38795465
15.
Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort.
Health Sci Rep
; 5(5): e719, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36000082
16.
Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
Int J Drug Policy
; 105: 103706, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35533635
17.
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.
Gastroenterology
; 138(1): 123-35.e1-2, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19782085
18.
Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort.
Int J Drug Policy
; 96: 103422, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34426040
19.
Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.
J Hepatol
; 53(4): 616-23, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20619475
20.
Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial.
Health Sci Rep
; 3(2): e151, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32270056